tiprankstipranks
Alliance Pharma PLC (GB:APH)
LSE:APH

Alliance Pharma (APH) Income Statement

20 Followers

Alliance Pharma Income Statement

Last quarter (Q4 2022), Alliance Pharma's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Alliance Pharma's net income was £―. See Alliance Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-£ 167.42M£ 163.21M£ 129.80M£ 135.64M£ 118.21M
Cost of Revenue
-£ 65.73M£ 53.76M£ 46.98M£ 49.56M£ 45.56M
Gross Profit
-£ 101.68M£ 109.45M£ 82.82M£ 86.08M£ 72.65M
Operating Expense
-£ 73.53M£ 78.88M£ 53.14M£ 48.35M£ 43.72M
Operating Income
-£ 28.16M£ 30.57M£ 29.67M£ 37.73M£ 28.92M
Net Non Operating Interest Income Expense
-£ -4.77M£ 3.62M£ -2.65M£ -3.75M£ -1.44M
Other Income Expense
------
Pretax Income
-£ 5.21M£ 18.16M£ 13.02M£ 31.08M£ 22.80M
Tax Provision
-£ 4.27M£ 10.84M£ 4.99M£ 6.07M£ 4.45M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ 936.00K£ 7.32M£ 8.03M£ 25.01M£ 18.36M
Basic EPS
--£ 0.01£ 0.02£ 0.05£ 0.04
Diluted EPS
--£ 0.01£ 0.02£ 0.05£ 0.04
Basic Average Shares
-£ 539.48M£ 535.30M£ 531.06M£ 520.69M£ 497.20M
Diluted Average Shares
-£ 545.28M£ 542.33M£ 537.32M£ 530.16M£ 510.42M
Dividend Per Share
--£ 0.02£ <0.01£ 0.02£ 0.01
Total Operating Income As Reported
------
Reported Normalized Basic E P S
---£ 0.05£ 0.05£ 0.05
Reported Normalized Diluted E P S
---£ 0.05£ 0.05£ 0.04
Rent Expense Supplemental
------
Total Expenses
-£ 139.26M£ -132.64M£ 100.13M£ 97.91M£ 89.28M
Net Income From Continuing And Discontinued Operation
-£ 936.00K£ 7.32M£ 8.03M£ 25.01M£ 18.36M
Normalized Income
-£ 22.45M£ 23.70M£ 17.41M£ 26.70M£ 22.60M
Interest Expense
---£ 2.08M£ 3.29M£ 3.04M
EBIT
-£ 9.99M£ 21.16M£ 15.09M£ 34.36M£ 25.84M
EBITDA
-£ 38.99M£ 21.16M£ 36.06M£ 36.32M£ 33.63M
Currency in GBP

Alliance Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis